Supplementary Material
Fig S1. Absolute change from baseline in the proportion of patients satisfied with treatmenta who initiated secukinumab who had baseline data and 6, 12, 18, and 24 months of follow-up.b
a Statement: “I believe this treatment is effective in clearing my skin of psoriasis” (1=strongly agree, 2=somewhat agree, 3=neither agree nor disagree, 4=somewhat disagree, 5=strongly disagree).
b Available effectiveness records for treatment satisfaction scores were reported based on the index visit or the visit closest to the index date. Baseline data were from enrolled patients who had 6-, 12-, 18-, and 24-month follow-up periods, respectively.
1
Fig S2. Median BSAa values at baseline and 6-, 12-, 18-, and 24-month follow-up in all patients who initiated secukinumab and at baseline and 6-, 12-, and 18-month follow-up in those
stratified by prior biologic or systemic use.b
2
BSA, body surface area.
a Available effectiveness records for affected BSA were reported based on the index visit or the visit closest to the index date with such values during the 12-month baseline period.
b Baseline data were from enrolled patients who had 6-,12-, 18-, and 24-month follow-up periods, respectively.
3
Fig S3. Median PGA×BSAa values at baseline and 6-, 12-, 18-, and 24-month follow-up in all patients who initiated secukinumab and at baseline and 6-, 12-, and 18-month follow-up in those stratified by prior biologic or systemic use.b
4
BSA, body surface area; PGA, Physician Global Assessment.
a Available effectiveness records for PGA scores and affected BSA were reported based on the index visit or the visit closest to the index date with such values during the 12-month baseline period.
b Baseline data were from enrolled patients who had 6-,12-, 18-, and 24-month follow-up periods, respectively.
5
